167 related articles for article (PubMed ID: 23954579)
21. Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in direct acting antiviral naive patients.
Grammatikos G; Jabara CB; Ahmad MQ; Herrmann E; Zeuzem S; Welsch C
Antivir Ther; 2014; 19(5):455-61. PubMed ID: 24457994
[TBL] [Abstract][Full Text] [Related]
22. Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches.
de Carvalho IM; Alves R; de Souza PA; da Silva EF; Mazo D; Carrilho FJ; Queiroz AT; Pessoa MG
J Med Virol; 2014 Oct; 86(10):1714-21. PubMed ID: 25042789
[TBL] [Abstract][Full Text] [Related]
23. A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome.
Bagaglio S; Hasson H; Peano L; Vercesi R; Messina E; Galli A; Foppa CU; Morsica G
Viruses; 2020 Feb; 12(3):. PubMed ID: 32121164
[TBL] [Abstract][Full Text] [Related]
24. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.
Franco S; Bellido R; Aparicio E; Cañete N; García-Retortillo M; Solà R; Tural C; Clotet B; Paredes R; Martínez MA
J Viral Hepat; 2011 Oct; 18(10):e578-82. PubMed ID: 21914079
[TBL] [Abstract][Full Text] [Related]
25. Is hepatitis C virus NS3 protease quasispecies heterogeneity predictive of progression from cirrhosis to hepatocellular carcinoma?
Vallet S; Gouriou S; Nkontchou G; Hotta H; Vilerio M; Legrand-Quillien MC; Beaugrand M; Trinchet JC; Nousbaum JB; Dény P; Gaudy C; Goudeau A; Picard B; Payan C
J Viral Hepat; 2007 Feb; 14(2):96-106. PubMed ID: 17244249
[TBL] [Abstract][Full Text] [Related]
26. Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV/HCV coinfected, treatment-naïve patients.
Cao Y; Bao Y; Xia W; Wu H; Wei F; Zhang Y; Zhang R; Xu X
Clin Res Hepatol Gastroenterol; 2016 Nov; 40(5):597-604. PubMed ID: 27016893
[TBL] [Abstract][Full Text] [Related]
27. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients.
Treviño A; de Mendoza C; Parra P; Rodríguez C; Madejón A; Plaza Z; del Romero J; Poveda E; Soriano V
Antivir Ther; 2011; 16(3):413-6. PubMed ID: 21555824
[TBL] [Abstract][Full Text] [Related]
28. Characterization of clinical predictors of naturally occurring NS3/NS4A protease polymorphism in genotype 1 hepatitis C virus mono and HIV co-infected patients.
Lisboa Neto G; Malta FM; Gomes-Gouvêa MS; Noble CF; Romano CM; Rebello Pinho JR; Silva MH; Leite AGB; Piccoli LZ; Carrilho FJ; Mendes-Correa MC
J Med Virol; 2017 Dec; 89(12):2249-2254. PubMed ID: 28700085
[TBL] [Abstract][Full Text] [Related]
29. HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors.
Ferraro D; Urone N; Di Marco V; Craxì A
Infect Genet Evol; 2014 Apr; 23():80-5. PubMed ID: 24508244
[TBL] [Abstract][Full Text] [Related]
30. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
31. Use of whole genome sequencing in the Dutch Acute HCV in HIV study: focus on transmitted antiviral resistance.
Christiansen MT; Hullegie SJ; Schutten M; Einer-Jensen K; Tutill HJ; Breuer J; Rijnders BJA
Clin Microbiol Infect; 2017 Feb; 23(2):123.e1-123.e4. PubMed ID: 27693529
[TBL] [Abstract][Full Text] [Related]
32. Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistance associated variant emergence in the Hepatitis C virus protease coding-region.
Irving WL; Rupp D; McClure CP; Than LM; Titman A; Ball JK; Steinmann E; Bartenschlager R; Pietschmann T; Brown RJ
Antiviral Res; 2014 Oct; 110():52-9. PubMed ID: 25057759
[TBL] [Abstract][Full Text] [Related]
33. Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors.
Bagaglio S; Messina E; Hasson H; Merli M; Andolina A; Lazzarin A; Uberti-Foppa C; Morsica G
New Microbiol; 2017 Jan; 40(1):53-55. PubMed ID: 28072886
[TBL] [Abstract][Full Text] [Related]
34. Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy.
Svarovskaia ES; Martin R; McHutchison JG; Miller MD; Mo H
J Clin Microbiol; 2012 Oct; 50(10):3267-74. PubMed ID: 22837328
[TBL] [Abstract][Full Text] [Related]
35. Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.
Bagaglio S; Messina E; Uberti-Foppa C; Merli M; Torre LD; Lazzarin A; Hasson H; Morsica G
J Antimicrob Chemother; 2013 Jun; 68(6):1448-50. PubMed ID: 23390206
[No Abstract] [Full Text] [Related]
36. Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus.
Lodrini S; Bagaglio S; Canducci F; De Mitri MS; Andreone P; Loggi E; Lazzarin A; Clementi M; Morsica G
J Biol Regul Homeost Agents; 2003; 17(2):198-204. PubMed ID: 14518724
[TBL] [Abstract][Full Text] [Related]
37. Characterization of HCV NS3 Protease Variants in HCV/HIV-Coinfected Patients by Ultra-Deep Sequence Analysis: Relationship with Hepatic Fibrosis.
Abdel-Hameed EA; Rouster SD; Zhang X; Chen J; Medvedovic M; Goodman ZD; Sherman KE
J Acquir Immune Defic Syndr; 2017 Mar; 74(3):353-358. PubMed ID: 27898525
[TBL] [Abstract][Full Text] [Related]
38. Conservation of hepatitis C virus nonstructural protein 3 amino acid sequence in viral isolates during liver transplantation.
Mello IM; Thumann C; Schvoerer E; Soulier E; Pinho JR; Silvestre DA; Queiroz AT; Wolf P; Baumert TF; Keller FS; Pereira CA
J Viral Hepat; 2009 Oct; 16(10):732-7. PubMed ID: 19486468
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis C in human immunodeficiency virus-coinfected patients: increased variability in the hypervariable envelope coding domain.
Sherman KE; Andreatta C; O'Brien J; Gutierrez A; Harris R
Hepatology; 1996 Apr; 23(4):688-94. PubMed ID: 8666318
[TBL] [Abstract][Full Text] [Related]
40. Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience.
Ruggiero T; Proietti A; Boglione L; Milia MG; Allice T; Burdino E; Orofino G; Bonora S; Di Perri G; Ghisetti V
Arch Virol; 2015 Nov; 160(11):2881-5. PubMed ID: 26249823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
